Microba Life Sciences (ASX:MAP) has received Human Research Ethics Committee approval for a Phase 1 clinical trial of its novel drug candidate MAP 315, a live biotherapeutic for the treatment of ulcerative colitis.

The trial will involve 32 healthy participants and be conducted by Nucleus Network in Melbourne, Australia.

The randomised, double-blind, placebo-controlled study will evaluate the drug's safety, tolerability, and pharmacokinetics in healthy adults.

Ulcerative colitis is a type of inflammatory bowel disease affecting over 7 million people worldwide, with existing treatment options often failing to achieve sustained remission.